TY  - JOUR
T1  - Overview of Myasthenia Gravis Subgroups and its influence on Pregnancy and their Treatment Advances
A1  - Ankita Wal
A1  - Pranay Wal
A1  - Ashutosh Pandey
A1  - Himangi Vig
A1  - Akash Ved
A1  - Himanshu Bhusan Samal
JF  - Pharmacophore
JO  - Pharmacophore
SN  - 2229-5402
Y1  - 2022
VL  - 13
IS  - 3
DO  - 10.51847/KvdmOxw5Gj
SP  - 19
EP  - 30
N2  - Antibodies that attack the neuromuscular junction induce myasthenia gravis, an immunological illness. Such antibodies assault and degrade postsynaptic molecules in by binding to the postsynaptic muscular end-plate. As a consequence, signal transduction is disrupted, resulting in muscular weakness and fatigability. Developments in our knowledge of the immunological mechanisms that cause myasthenia gravis have paved the way for the development of new targeted immunity treatments. The majority of myasthenia gravis sufferers have a well-managed condition with just minor to moderate symptoms. The goal must be to create more targeted therapies that reduce or enhance tolerance to the well-known and particular autoimmune reactions that result in autoantibody formation and muscular weakening. Several drugs widely used in obstetrics can aggravate the condition. The impact of maternity on myasthenia varies greatly from one woman to the next, as well as from one pregnancy to the next within the same woman. Acetylcholine esterase inhibitors, corticosteroids, and other immunosuppressants, as well as proper rest, are the most common therapy. Intrauterine antibody exposure can cause in utero or neonatal effects in newborns, which are usually temporary. This review focuses on myasthenia gravis subgroups and treatment breakthroughs, as well as the influence of myasthenia gravis on pregnancy and its management.
UR  - https://pharmacophorejournal.com/article/overview-of-myasthenia-gravis-subgroups-and-its-influence-on-pregnancy-and-their-treatment-advances-8llmrsavd5deh9v
ER  -